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Background: BoneXpert (BX) is a newly developed medical device based on digital X-ray radiogrammetry to
measure human cortical bone thickness. The aim of this study was to quantify cortical bone loss of the metacarpals
in patients with psoriatic arthritis (PsA) and compare these findings with other radiological scoring methods.
Methods: The study includes 104 patients with verified PsA. The BX method was used to measure the Metacarpal Index
(MCI) at the metacarpal bones (II–IV). Additionally, the T-score of the MCI (T-scoreMCI) was calculated. Radiographic severity
was determined by the Psoriatic Arthritis Ratingen Score (Proliferation Score and Destruction Score) as published by
Wassenberg et al. and the Psoriatic Arthritis modified van der Heijde Sharp Score (Joint Space Narrowing Score and
Erosion Score).
Results: For the total PsA study cohort, the T-scoreMCI was significantly reduced by −1.289 ± 1.313 SD. The MCI negatively
correlated with the Proliferation Score (r = −0.732; p < 0.001) and the Destruction Score (r = −0.771; p < 0.001) of the
Psoriatic Arthritis Ratingen Score. Lower coefficients of correlations were observed for the Psoriatic Arthritis modified
van der Heijde Sharp Score. In this context, a severity-dependent and PsA-related periarticular demineralisation as
measured by the MCI was quantified. The strongest reduction of −30.8 % (p < 0.01) was observed for the MCI in the
Destruction Score.
Conclusions: The BX MCI score showed periarticular demineralisation and severity-dependent bone loss in patients
with PsA. The measurements of the BX technique were able to sensitively differentiate between the different stages of
disease manifestation affecting bone integrity and thereby seem to achieve the potential to be a surrogate marker of
radiographic progression in PsA.
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Periarticular demineralisationBackground
Psoriatic arthritis (PsA) is an inflammatory disease char-
acterised by progressive joint destruction and related
disability based on enthesitis as well as synovitis, often
affecting the small joints of the hand [1]. The radio-
graphic damage in PsA presents a wide spectrum of joint
destruction which includes periarticular demineralisation
and erosions, joint space narrowing, ankyloses of the
joints, malalignment and subluxation of the affected
joints and new bony formation with periosteal reaction* Correspondence: alexander.pfeil@med.uni-jena.de
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also in clinical trials. In the last decades, scoring
methods (e.g. Psoriatic Arthritis Ratingen Score and
Psoriatic Arthritis modified van der Heijde Sharp Score
(SHS Score)) were established to measure the radio-
graphic damage in PsA [3].
Digital X-ray radiogrammetry (DXR) is a computer-
based technique for measuring cortical thickness, and
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Age (years), mean ± SD 54.7 ± 12.3
Height (cm), mean ± SD 168 ± 9.0
Weight (kg), mean ± SD 79 ± 16.7
Body mass index, mean ± SD 27.6 ± 5.2
Disease duration (years), mean ± SD 9.6 ± 6.7
Tender joint count (0–28 joints), mean ± SD 2.5 ± 2.5
Swollen joint count (0–28 joints), mean ± SD 2.3 ± 2.5
C-reactive protein (mg/l), mean ± SD 9.8 ± 14.2
Erythrocyte sedimentation rate
(mm/hour), mean ± SD
16.3 ± 17.1
Corticosteroids, n (%)
Yes (mean dose 5 mg/day) 28 (26.9)
No 76 (73.1)








Fig. 1 Screen view of BX analysis with the positioned ROI (green dots)
for the measurement of cortical thickness at metacarpals II–IV
Pfeil et al. Arthritis Research & Therapy  (2016) 18:248 Page 2 of 9common application of DXR is the quantification of
inflammatory-associated periarticular metacarpal bone
loss in patients with RA [6]. Periarticular bone loss de-
tected by DXR is strongly associated with disease activity
in RA [7] and radiographic progression [8]. Additionally,
two initial studies investigated periarticular bone loss in
PsA [9, 10].
BoneXpert (BX) is a more advanced DXR technique
using computer-assisted diagnosis software for the ana-
lysis of the metacarpal bones [11–18]. This new version
is now available for the measurement of the Metacarpal
Index (MCI) and the quantification of periarticular min-
eralisation in adults. The clinical advantage of the BX
technique consists of its integration into a PACS system
as well as into a PACS workflow to reveal a direct image
analysis and quantification of periarticular bone loss.
The aim of this study was to evaluate the presence of
periarticular cortical bone loss of the metacarpals in pa-
tients with PsA using BX and to compare these findings
with the established radiological scoring methods. If BX
is able to measure bone loss more sensitively it may be




A total of 104 PsA patients (57 female, 47 male) fulfilling
the CASPAR criteria [19] were included in the study.
Radiographs of the hand were performed on all subjects
using standardised technical conditions. There was no
pre-selection due to severity of PsA or if steroid therapy
had been given. All patients were treated either with non-
steroidal anti-inflammatory drugs or disease-modifying
antirheumatic drugs (details see Table 1).
Measurement of cortical hand bone mass by BX
The BX system (version 2.3.0.4; Visiana, Holte, Denmark)
is a computer-assisted diagnostic technique for the radio-
geometrical analysis of the metacarpal bones on plain
radiographs. All plain radiographs (anterior–posterior
projection) of the non-dominant hand were acquired by
the same X-ray devices using standardised conditions.
The edge of each metacarpal diaphysis was defined
using 32 points which corresponded to the same ana-
tomical locations across all subjects [20, 21]. Two of the
points corresponded to the proximal and distal ends of
the metacarpal bone, and these markers were used to
define the bone axis. The length (L) of the bone was
measured along this axis, including the epiphysis. A re-
gion of interest (ROI) was positioned at 44 % of L from
the proximal end of the bone, and it extended to 25 % of
L. The ROIs were located at the metacarpal bones II–IV
(see Fig. 1). In this region, the inner and outer edges of
the cortical bone partition were determined as follows:the outer cortical edge was the location with the max-
imal gradient and the inner cortical edge was detected
as an intensity maximum [21].
Based on the ROI for each metacarpal bone, the aver-
age width (W) and the average cortical thickness (T)
were determined and expressed as the mean for the
metacarpal bones II–IV in millimetres [21].
The cortical area (A) was estimated by the defined
formula for a cylindrically symmetric bone model [21]:
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Additionally, the MCI was computed as the T divided
by the W which was later refined to [21]:
MCI ¼ A = W2
Based on the A as well as the metacarpal bone length (L)
and W, the Bone Health Index (BHI) was computed as:
BHI ¼ A = W1:333L0:333 
Scoring of hand radiographs
Each radiograph of the PsA cohort was scored by two
independent radiologists using the same scoring methods.
In the cases of ambiguity, a third highly experienced radi-
ologist reviewed the radiographs for a final decision.
Psoriatic Arthritis Ratingen Score
The Destruction Score and the Proliferation Score pub-
lished by Wassenberg et al. [22] are bicompartment
scores used to determine the extent of destructive
change (destruction) and the presence of bony growth
(proliferation) regarding the joints of the hand and feet
in PsA.
The Destruction Score segment indicates the percentage
of the joint surface destruction of the articulation with the
following scoring: score 0 = normal, score 1 = one or more
erosions with destruction of up to 10 %, score 2 = 11–25 %,
score 3 = 26–50 %, score 4 = 51–75 % and score 5 = >75 %
joint surface destruction.
The Proliferation Score segment evaluates PsA-related
bony proliferation using the following grading: score
0 = normal, score 1 = bone proliferation of 1–2 mm or
bone growth < 25 % of the original size (diameter),
score 2 = bone proliferation 2–3 mm or bone growth
with 25–50 %, score 3 = bone proliferation > 3 mm or
bone growth > 50 % and score 4 = ankylosis.
The Destruction Score (0–200) and the Proliferation
Score (0–160) are added together for a total score of
between 0 and 360 points. The individual sum of scor-
ing points is then divided by the number of evaluated
joints [22].
SHS Score
The Erosion Score segment (total sum points: 280) and
the Joint Space Narrowing Score segment (total sum
points: 168) [23] of the hand and feet joints were deter-
mined using the SHS Score. To assess PsA-specific
radiological damage, scores for the distal interphalangeal
hand joints and pencil-in-cup/gross osteolysis deform-
ities were added to the original SHS Score as published
by Kavanaugh et al. [24]. The SHS Score thus ranged
from 0 to 528 (total score sum) which is a composite of
the erosion score (0–320) and the joint space narrowingscore (0–208) [24]. Additionally, the individual sums of
the scoring points were then divided by the number of
evaluated joints.
Statistical analysis
The statistical analysis was performed using SPSS
Version 21.0® (SPSS, Chicago, IL, USA), for Windows.
To evaluate reproducibility, 10 measurements of the
same radiograph per score were repeated. The results
were expressed as mean and standard deviation (SD)
and reproducibility errors as a coefficient of variation
(CV). The coefficients of variation are typically given on
a percentage basis:
CV %ð Þ ¼ standard deviation=meanð Þ  100 %:
The Pearson coefficient of correlation was used to in-
vestigate the association between the BX parameters,
age, gender, the Psoriatic Arthritis Ratingen Score as
well as the SHS Score.
Thodberg et al. [25] published reference curves for the
MCI including healthy European adults. The peak MCI
for males is determined at the age of 28 years (MCI
0.6055 ± 0.0509) and for females at the age of 36 years
(0.60264 ± 0.0535) [25]. Based on the reference curves
and the peak MCI, the T-scoreMCI of the MCI as a com-
parative measurement with healthy subjects could be
determined. The T-score is calculated as follows [25]:
T−ScoreMCI ¼ MCIpatient –MCIpeak
 
=SDpeak
The reduction of all BX parameters for the different
scores was assessed using the Mann–Whitney U test.
The differences in BX parameters between patients
with and without erosions were compared by the
Mann–Whitney U test.
Sensitivity and specificity of MCI concerning the detec-
tion of erosions were based on receiver operating charac-
teristic (ROC) curve analysis. The MCI mean value of the
patients with erosions was used as the cut-off value.
The overall significance level was p < 0.05.
Results
Baseline characteristics
A total of 104 PsA patients (57 women and 47 men) were
included in the analysis (see Table 1). The mean disease
duration was 9.6 ± 6.7 years. The mean C-reactive protein
was 9.8 mg/l and/or the mean erythrocyte sedimentation
rate in the first hour was 16.3 mm. In this context, the
mean tender joint count was 2.5 ± 2.5 joints and the mean
swollen joint count was 2.3 ± 2.5 joints. Forty-nine patients
(47.1 %) were treated with non-steroidal anti-inflammatory
drugs, 42 patients (40.4 %) received synthetic disease-
modifying antirheumatic drugs and 13 patients (12.5 %) re-
ceived biological disease-modifying antirheumatic drugs.
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were treated with corticosteroids (mean dose 5 mg/day)
and 76 patients (73.1 %) received no corticosteroids.
Reproducibility
The CV was 0 % for BX parameters regarding the
Destruction and Proliferation Scores (Psoriatic Arthritis
Ratingen Score) and the Erosion and Joint Space Scores
(SHS Score).
BX measurements for the PsA cohort
For the entire PsA study, the T-score of the MCI
was −1.289 ± 1.313 SD. Regarding the association of age
and BX parameters, a low significant correlation was eval-
uated (MCI: r = −0.585, p < 0.001; T-scoreMCI: r = −0.586;
p < 0.001; T: r = −0.481; p < 0.001). W revealed no signifi-
cant correlation with age. A significant correlation be-
tween the BX parameters and gender was not observed.
BX measurements compared with standard scoring
methods
Psoriatic Arthritis Ratingen Score
The BHI, MCI, T-scoreMCI and T presented significant
negative coefficients of correlation with the different
scores. The highest negative correlation was observed be-
tween the MCI (r = −0.771; p < 0.001) or the T-scoreMCI
(r = −0.775; p < 0.001) and the Destruction Score. Similar
results were detected between the Proliferation Score for
the MCI (r = −0.732; p < 0.001) versus the T-scoreMCI
(r = −0.744; p < 0.001). The BHI revealed a significant
negative coefficient of correlation (r = −0.682; p < 0.01) for
the Destruction Score and the Proliferation Score. W
presented no significant coefficients of correlations to
both scores.
SHS Score
Lower negative coefficients of correlation were observed
between MCI, T-scoreMCI and BHI and the Joint Space
Narrowing Score (MCI: r = −0.558, p < 0.001; T-scoreMCI:
r = −0.552, p < 0.001; BHI: r = 0.522, p < 0.01) or the
Erosion Score (MCI: r = −0.714, p < 0.001; T-scoreMCI:
r = −0.715, p < 0.001; BHI: r = 0.660, p < 0.01). W also
showed no significant coefficients of correlation regarding
the SHS Score.
BX results show bone loss depending on severity of PsA
Psoriatic Arthritis Ratingen Score
Proliferation Score For the Proliferation Score, MCI
(−28.3 %, p < 0.01) and T-scoreMCI significantly differed
from 0.596 ± 0.052 (score 0) to 0.427 ± 0.045 (score 4)
and from −0.427 ± 0.927 SD (score 0) to −3.616 ± 0.838,
respectively (Table 2). The relative difference of T
was −31.9 %. In this context, BHI presented a significant
difference of −24.6 % (p < 0.01) from 5.85 ± 0.42 (score 0)to 4.41 ± 0.52 (score 4). W showed no significant changes
between score 0 and score 4.
Destruction Score Using the Destruction Score, BHI
presented a significant difference with −24.8 % (p < 0.01)
from 5.88 ± 0.41 (score 0) to 4.42 ± 0.75 (score 5)
(Table 2). MCI and T were also significantly differed
between score 0 and score 5 with −30.8 % (p < 0.01)
and −30.9 % (p < 0.01), respectively. The T-scoreMCI was
significantly changed from −0.346 ± 0.926 (score 0)
to −3.813 ± 1.035 (score 5). In accordance with the
Proliferation Score for W, no significant differences were
evaluated.
SHS Score
Erosion Score MCI revealed a significant difference
of −28.5 % (p < 0.01) from 0.601 ± 0.059 (score 0) to
0.430 ± 0.046 (score 5) and T-scoreMCI showed a signifi-
cant difference from −0.324 ± 1.039 (score 0) to −3.510 ±
0.912 (score 5) (Table 3). The T and BHI presented
comparable differences with −31.3 % (p < 0.01) and −24.6 %
(p < 0.01). W revealed no significant severity dependent
change.
Joint Space Narrowing Score The Joint Space Narrowing
Score presented a difference of the BHI (−21.1 %, p < 0.01)
from 5.73 ± 0.57 (score 0) to 4.52 ± 0.52 (score 4) (Table 3).
MCI (−24.9 %) and T-scoreMCI observed a significant dif-
ference from 0.582 ± 0.063 (score 0) to 0.437 ± 0.050
(score 4) and from −0.681 ± 1.163 (score 0) to −3.416 ±
0.952 (score 4) respectively. T revealed a significant
difference of −26.8 % (p < 0.01). Finally, W presented a
non-significant difference with 8.8 %.
BX parameters in dependence on the occurrence of
erosions
PsA patients with erosions presented a significantly
(p < 0.01) lower BHI (−10.2 %), MCI (−12.5 %) and T
(−13.9 %) compared with patients without erosion
(Table 4). In this context, the T-scoreMCI in PsA patients
with erosions was significant lower (−1.722) than in
patients without erosions (−0.324). W (4.4 %; p =NS) re-
vealed no significant change between patients with and
without erosions.
The sensitivity and specificity of the MCI regarding
the detection of erosions was 88 % versus 49 % (accuracy
81 %, p < 0.01).
Discussion
The BX technique is a recently developed automated
method for the measurement of the MCI based on the
radiogeometrical analysis of metacarpal bones. The aim
of this study was to evaluate the presence of periarticular
cortical bone loss of the metacarpal bones in patients
Table 2 BoneXpert parameters in PsA patients stratified by Psoriatic Arthritis Ratingen Score Proliferation and Destruction Scores
Proliferation Score BHI MCI T-scoreMCI T W Destruction Score BHI MCI T-scoreMCI T W
0 (n = 34) 5.85 (0.42) 0.596 (0.052) −0.427 (0.927) 2.04 (0.26) 8.02 (1.05) 0 (n = 41) 5.88 (0.41) 0.600 (0.053) −0.346 (0.926) 2.07 (0.25) 8.02 (1.02)
1 (n = 28) 5.74 (0.43) 0.576 (0.051) −0.762 (0.911) 1.99 (0.25) 8.24 (1.05) 1 (n = 14) 5.73 (0.39) 0.575 (0.039) −0.805 (0.710) 1.99 (0.23) 8.23 (1.07)
2 (n =17) 5.32 (0.45) 0.531 (0.034) −1.611 (0.648) 1.81 (0.30) 8.37 (1.13) 2 (n =12) 5.44 (0.45) 0.551 (0.026) −1.281 (0.547) 1.84 (0.29) 8.06 (1.14)
3 (n = 14) 5.19 (0.47) 0.505 (0.041) −2.138 (0.819) 1.73 (0.26) 8.57 (0.84) 3 (n = 16) 5.17 (0.44) 0.513 (0.029) −1.981 (0.627) 1.73 (0.24) 8.32 (0.80)
4 (n = 11) 4.41 (0.52) 0.427 (0.045) −3.616 (0.838) 1.39 (0.23) 8.58 (1.20) 4 (n = 13) 5.10 (0.49) 0.494 (0.043) −2.300 (0.839) 1.72 (0.27) 8.78 (1.03)
– – – – – – 5 (n = 8) 4.42 (0.75) 0.415 (0.051) −3.813 (1.035) 1.43 (0.39) 9.04 (1.20)
Absolute and relative changes









Absolute and relative changes









Significance <0.01 <0.01 <0.01 <0.01 NS Significance <0.01 <0.01 <0.01 <0.01 NS
Data presented as mean (standard deviation)












Table 3 BoneXpert parameters in PsA patients stratified by SHS Erosion and joint space narrowing scores
Erosion Score BHI MCI T-scoreMCI T W Joint Space Narrowing Score BHI MCI T-scoreMCI T W
0 (n = 33) 5.90 (0.49) 0.601 (0.059) −0.324 (1.039) 2.08 (0.28) 8.03 (0.95) 0 (n = 35) 5.73 (0.57) 0.582 (0.063) −0.681 (1.163) 1.98 (0.32) 7.99 (0.89)
1 (n = 13) 5.80 (0.46) 0.593 (0.042) −0.554 (0.845) 2.00 (0.28) 7.85 (0.89) 1 (n = 26) 5.65 (0.46) 0.568 (0.058) −0.986 (1.055) 1.96 (0.25) 8.66 (0.94)
2 (n =13) 5.59 (0.58) 0.553 (0.055) −1.154 (1.104) 1.95 (0.33) 8.51 (1.09) 2 (n =16) 5.57 (0.43) 0.547 (0.032) −1.289 (0.591) 1.94 (0.26) 8.19 (1.20)
3 (n = 19) 5.28 (0.32) 0.523 (0.028) −1.800 (0.536) 1.77 (0.21) 8.41 (1.20) 3 (n = 15) 5.34 (0.55) 0.537 (0.061) −1.457 (1.153) 1.82 (0.32) 8.29 (1.16)
4 (n = 16) 5.22 (0.36) 0.515 (0.042) −1.923 (0.754) 1.75 (0.22) 8.46 (1.16) 4 (n = 12) 4.52 (0.52) 0.437 (0.050) −3.416 (0.952) 1.45 (0.23) 8.69 (1.04)
5 (n = 10) 4.45 (0.55) 0.430 (0.046) −3.510 (0.912) 1.43 (0.25) 8.70 (0.95) – – – – – –
Absolute and relative changes









Absolute and relative changes









Significance <0.01 <0.01 <0.01 <0.01 NS Significance <0.01 <0.01 <0.01 <0.01 NS
Data presented as mean (standard deviation)













Table 4 Changes of BX parameters dependent on the existence
of bone erosions





BHI mean (SD) 5.90 (0.49) 5.30 (0.60) −10.2 % (p < 0.01)
MCI mean (SD) 0.601 (0.059) 0.526 (0.063) −12.5 % (p < 0.01)
T-scoreMCI
mean (SD)
−0.324 (1.039) −1.722 (1.190) 1.398 (p < 0.01)
T mean (SD) 2.08 (0.28) 1.79 (0.31) −13.9 % (p < 0.01)
W mean (SD) 8.03 (0.95) 8.38 (1.09) 4.4 (p = NS)
Data presented as mean (standard deviation)
BHI Bone Health Index, BX BoneXpert, MCI Metacarpal Index, NS not significant,
T cortical thickness of the metacarpal bone, W width of the metacarpal bone
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findings with different scoring methods.
The MCI is an established measurement for the quanti-
fication of metacarpal bone loss, particularly in rheuma-
toid arthritis [26]. The T-scoreMCI of the MCI presented a
significantly reduced negative value with −1.289 ± 1.313 in
all PsA patients. The reduced T-scoreMCI was clearly asso-
ciated with a reduced bone mineral density of the meta-
carpal bones in PsA. Kocijan et al. [27] also found a
reduced trabecular bone mineral density of the distal ra-
dius and periarticular radius with −12.0 % versus −8.1 %
using high-resolution peripheral quantitative computed
tomography, in which the bone mineral density was mea-
sured proximal to the affected joints.
The comparison of the BX parameters (i.e. MCI) with
the SHS Score presented equal coefficients of correla-
tions as reported by Böttcher et al. [8] between the MCI
as measured by the X-posure System (the traditional
DXR system) and the Sharp Score in patients with
rheumatoid arthritis. Focusing on the Proliferation Score
and the Destruction Score of the Psoriatic Arthritis
Ratingen Score [22], high coefficients of correlation were
observed for MCI, precisely reflecting the radiographic
changes in PsA by the Proliferation and Destruction
Scores.
For all scores, the study found a severity-dependent
reduction for the BX parameters (MCI, T-scoreMCI, T
and BHI) in PsA patients. The strongest reductions were
observed for MCI and T using the Proliferation Score
(MCI: −28.3 %; T: −31.9 %) and the Destruction Score
(MCI: −30.8 %; T: −30.9 %). The reduced MCI and T is
directly associated with cortical thinning and the peri-
articular demineralisation of the metacarpal bones. Such
cortical thinning and periarticular demineralisation show
direct association with bone destruction and bone pro-
liferation in PsA. Different cross-sectional studies have
reported a strong relationship between reduced meta-
carpal bone mineral density and MCI as measured by
the X-posure System and radiographic joint destruction[8, 26]. For the Sharp Joint Space Narrowing Score and
the Sharp Erosion Score a reduced MCI was found
(−28.6 % versus −22.1 %) in RA patients [8].
The study also presented a lower MCI (−12.5 %, p < 0.01)
and cortical thickness as detected by T (−13.9 %, p < 0.01)
in patients with erosions compared with patients without
erosions. These results indicate that the occurrence of
erosions is associated with periarticular bone loss.
Additionally, the BX technique presented a sensitivity and
specificity of 88 % versus 49 % using MCI for the
detection of erosions. In this context, the traditional DXR
technique showed a sensitivity of 87 % and a specificity of
49 % (for the MCI) in the detection of rheumatoid
arthritis [28].
The measurement of periarticular bone loss can be
considered a complementary approach to verify PsA-
related bony changes and a surrogate marker for PsA
progression. The quantification of periarticular deminer-
alisation based on the cortical indices is potentially influ-
enced by the size of the patient. The BHI offers the
advantage to quantify cortical thickness and periarticular
demineralisation independent of the size of the patient,
leading to a better understanding of cortical change.
One limitation of the study is the absence of healthy
controls in the BX analysis. The healthy reference cohort
data were published by Thodberg et al. [25] and the
study used the T-scoreMCI to quantify the periarticular
demineralisation in comparison with healthy subjects.
Additionally, a limitation of the study is the absence of
longitudinal data regarding therapeutic effects. Hoff
et al. [9] presented data about the inhibition of peri-
articular demineralisation detected by the traditional
DXR technique in PsA patients under anti-tumour
necrosis factor treatment with infliximab. In this con-
text, the quantification of periarticular demineralisation
seems to be a marker for the response of therapy in PsA
[9]. However, the data of the study should be used as a
basis to compare different treatment strategies in PsA by
the BX technique.
Conclusions
The development of digital imaging and computer-
assisted diagnostic methods has enabled a more precise
quantification of periarticular demineralisation by the
new BX technique. Patients with PsA showed reduced
periarticular mineralisation as measured by the MCI and
the T-scoreMCI. Additionally, the BX measurements re-
vealed a strong association with the radiographic scoring
methods. This new medical device offered the opportun-
ity to quantify severity-dependent periarticular deminer-
alisation in PsA patients with high reproducibility and
can function as a surrogate marker of radiographic pro-
gression to consecutively optimise an appropriate indi-
vidual therapeutic strategy.
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of metacarpal bone (mm) measured by BoneXpert
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